Trials / Completed
CompletedNCT00856362
Study Evaluating The Co-Administration Of Moxidectin And Midazolam In Healthy Subjects
An Open-label, Single-Dose, 4-Period, Sequential Study to Determine the Effect of Moxidectin on CYP3A4 Activity in Healthy Subjects Using Midazolam as a Probe Substrate
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 38 (estimated)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the effect of single doses of midazolam on the plasma concentration of a single dose of moxidectin in healthy young adult subjects, and to assess the safety of co-administration of moxidectin and midazolam.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Moxidectin | |
| DRUG | Midazolam |
Timeline
- Start date
- 2009-04-01
- Primary completion
- 2009-09-01
- Completion
- 2009-09-01
- First posted
- 2009-03-05
- Last updated
- 2010-09-16
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00856362. Inclusion in this directory is not an endorsement.